Short answer
Axsome Therapeutics, Inc. (AXSM) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $191M (up 57.4% year over year) with net income of −$65M.
Q1 2026 key financials · XBRL
- Revenue
- $191M
- +57.4% YoY
- Net income
- −$65M
- −8.6% YoY
- Operating margin
- -33.1%
- EPS (diluted)
- −$1.26
- −3.3% YoY
Source: XBRL data from the Axsome Therapeutics, Inc. (AXSM) Q1 2026 10-Q on SEC EDGAR. USD.
Axsome Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly expanded tariff risk, triggered by April 2026 Section 232 proclamation authorizing potential 100% tariffs on patented pharmaceuticals and ingredients
- Most materially updated policy risk, with BIOSECURE Act restrictions on government dealings involving designated Chinese biotechnology companies
- Regulatory compliance exposure, including potential penalties for healthcare-law violations involving fraud, abuse, transparency, privacy, and data security
- Near-term commercialization risk from manufacturing-partner changes required to avoid tariffs, potentially disrupting supply and compliance
- Financial risk from $570.0 million Blackstone facility, variable SOFR-based interest, and $30.0 million minimum liquidity covenant
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axsome Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.